BDX Newsletter May 2025

BDX: A Transformative Qtr for BCAL – Commercial Launch & First Revenues

Turning Point: BCAL Delivers First Revenues with BREASTESTplus™ Launch A Letter to Our Shareholders We are pleased to report that the March 2025 quarter marked a pivotal transformation for BCAL Diagnostics, as the commenced commercial operations, achieving its first revenues. The successful commercial launch of BREASTESTplus™ was a key milestone achieved in the quarter, and we could not have reached this point without the invaluable support of our Shareholders. Your belief in our vision, and your continued investment of both capital and trust, has been instrumental in bringing BCAL to this point. Your confidence in our team and our mission has been a constant source of motivation. Please see our full letter of appreciation sent to Shareholders at the end of March. If you are a shareholder and did not receive this letter directly, please provide your email contact details to BCAL’s share registry, Automic Pty Ltd by visitingwww.automic.com.auor email[email protected]. Letter to Shareholders Commercial Launch of BREASTESTplus™ In late March 2025, BCAL launched BREASTESTplus™ at the Sydney Breast Clinic, marking our first commercial offering. This first-in-class blood test for breast cancer diagnosis complements mammogram for women 30 and over with known high breast density. The controlled launch is a foundational step in our national rollout of BREASTESTplus™. The company is leveraging this initial site to expand into additional specialist clinics across New South Wales and Victoria throughout 2025, with plans for broader nationwide access to follow. BCAL’s CEO, Shane Ryan was joined by Breast Surgeon and Chair of BCAL’s Clinical Advisory Board, Dr David Speakman OAM for an Investor Webinar discussing the launch of BREASTESTplus™. Investors can access a recording of the webinar by registeringat the link below. BCAL Webinar

Get Clinical Support Health care professionals can contact the BCAL Diagnostics market access support team on1300 222 539(1300BCALDX) or visit the Healthcare Professionals Portal on our website athttps://www.bcaldiagnostics.com BREASTESTplus™ available as part of comprehensive breast screening BREASTESTplus™ is the first product for BCAL Diagnostics in the BREASTEST® technology range. BREASTESTplus™ is a new blood test designed for women with high breast density, used alongside breast imaging to help rule out the presence of breast cancer as part of a comprehensive screening strategy. Women interested in more information about BREASTESTplus™ are encouraged to speak with their breast specialist. Eligibility requirements apply. Further information is available atwww.bcaldiagnostics.comor contact a member of the BCAL support team at[email protected]. Building Clinical Confidence: Partnering with Specialists for Broader Adoption BCAL is advancing a targeted market access and doctor engagement strategy in preparation for the broader rollout of BREASTESTplus™ across Sydney and Melbourne. A key focus this quarter has been partnering with breast cancer specialists to build awareness, clinical confidence, and long-term adoption of our breakthrough blood test. Working closely with our Clinical Advisory Board and a growing network of Key Opinion Leaders (KOLs), BCAL is fostering peer-to-peer education and practical integration of BREASTESTplus™ into clinical practice. These trusted clinical partners are essential to driving uptake of the test for women with dense breast tissue. Additionally, BCAL is laying the groundwork for participation in major medical conferences in Australia and internationally to build clinical credibility and showcase the scientific value of BREASTESTplus™ to leading specialists in breast health. Clinical Validation Achieved, IP Fortified Through 2043 BCAL's research and development activities continue to advance, supported by our dedicated team of laboratory scientists. In the March quarter, the team successfully completed validation required for expanded NATA accreditation, enabling the launch of BREASTESTplus™. We continue sample collection laying the groundwork for the development of next-generation breast cancer diagnostics. At the same time, BCAL continued to strengthen its global intellectual property portfolio. A major milestone this quarter was the granting of our Australian patent for BCAL’sDiagnostic Signature, securing IP protection through to 2043. Together, our scientific validation and IP strategy are critical pillars supporting the clinical, commercial, and global potential of the BREASTEST® platform. Accelerating Access: BREASTESTplus™ Expands to Key Clinics in Sydney and Melbourne In May, BCAL was pleased to announce access to BREASTESTplus™ will be available at three additional specialist breast clinics in Sydney and Melbourne, with services commencing mid-May 2025. This follows the successful commercial launch in March and forms part of BCAL’s strategic, phased national rollout. New participating clinics include: Strathfield Breast Centre, Strathfield Private Hospital (Sydney) Lakeside Specialist Breast Clinic, Lakeview Private Hospital (Sydney) Southern Breast Oncology Services, Bentleigh East (Melbourne) This expansion reflects growing clinical demand and strengthens BCAL’s commitment to improving early breast cancer detection in women with high breast density, where traditional imaging methods may be limited. The rollout remains on track and will continue across additional metro and regional areas throughout 2025, with a focus on supporting breast specialists and enhancing patient access to innovative diagnostic solutions. Access the full market announcementhere. BREASTEST plus 2025 March Quarter Financial Snapshot As at 31 March2025, BCAL Diagnostics maintained a strong cash balance of $5 million, providing a solid financial foundation as the company accelerates the commercial rollout of BREASTESTplus™. Quarterly expenditure was $1.94 million, in line with expectations and aligned with BCAL’s operational and strategic goals for FY25. Payments to directors totalled $0.2 million, covering board fees and salaries. With BREASTESTplus™ now addressing a key gap in in comprehensive screening for women with dense breasts — where traditional breast imaging may be less effective — BCAL’s launch comes at a critical time. As nearly half of Australian women aged 50 to 74 remain unscreened, the company is focused on expanding access, deepening clinical engagement, and progressing next-generation diagnostics, all while managing resources to support long-term impact and shareholder value. Read BCAL Diagnostics 2025 March Quarter Activities Reporthere. 4C & March Quarter Activities Report Jayne Shaw Makes History at Women Changing the World Awards In a standout moment this quarter, Executive Chair Jayne Shaw, was honored at theWomen Changing the World Awards2025in London, UK. Jayne took 1stplace in all three nominated categories: Women in Health Healthcare Innovation Healthcare Additionally, Jayne was awarded the prestigiousGolden Heart Bronze Award, in recognition of Jayne’s tireless drive to improve the health outcomes for women and BCAL's leadership in women’s health innovation. This marked the first time a nominee has swept all categories at the event, which featured 872 attendees from 52 countries. Thank you from the BCAL team for your ongoing support! To unsubscribe to the BCAL Investor Newsletter please message[email protected] Women Changing the World Awards